What is the recommended TLD (dolutegravir 50 mg/tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg) regimen for a treatment‑naïve adult with normal renal function and no hepatitis B, and what alternative regimens should be used if renal impairment, drug intolerance, or hepatitis B develop?

TLD Regimen for Treatment-Naïve Adults with HIV

Recommended Initial Regimen

For treatment-naïve adults with normal renal function and no hepatitis B coinfection, the TLD regimen (dolutegravir 50 mg/tenofovir disoproxil fumarate 300 mg/lamivudine 300 mg) is administered as one fixed-dose combination tablet taken orally once daily. 1, 2, 3

• The standard dosing is dolutegravir 50 mg once daily combined with tenofovir disoproxil fumarate 300 mg once daily and lamivudine 300 mg once daily 1, 2, 3
• This regimen can be taken with or without food 3
• The 2024 International Antiviral Society-USA Panel recommends dolutegravir-based regimens as preferred initial therapy for treatment-naïve adults 1

Management of Renal Impairment

When renal impairment develops (estimated creatinine clearance <50 mL/min), the dosing interval for tenofovir disoproxil fumarate must be modified, or an alternative regimen should be used. 3, 4

Specific Renal Dosing Adjustments:

• CrCl ≥50 mL/min: No dose adjustment needed 3, 4
• CrCl 30-49 mL/min (moderate impairment): Tenofovir disoproxil fumarate 300 mg every 48 hours 4
• CrCl 10-29 mL/min (severe impairment): Tenofovir disoproxil fumarate 300 mg every 72-96 hours 4
• End-stage renal disease on hemodialysis: Tenofovir disoproxil fumarate 300 mg every 7 days after dialysis session 4

Alternative Regimen for Renal Impairment:

Switch to dolutegravir plus lamivudine (DTG/3TC) as a two-drug regimen when tenofovir cannot be continued due to renal dysfunction. 1

• This eliminates tenofovir-related nephrotoxicity while maintaining virologic suppression 1
• Dolutegravir and lamivudine do not require dose adjustment until severe renal impairment 2
• For lamivudine: doses must be adjusted when CrCl falls below normal, though specific adjustments are required per renal function 2

Management of Hepatitis B Coinfection

When hepatitis B coinfection is present, the TLD regimen must be continued indefinitely, as both tenofovir and lamivudine provide anti-HBV activity; discontinuation risks severe hepatitis B flares. 5, 1

Key Hepatitis B Management Principles:

• Lamivudine dosing for HIV/HBV coinfection: 150 mg twice daily (300 mg total daily) as part of combination antiretroviral therapy 6
• Never use lamivudine alone for HBV treatment in HIV-coinfected patients due to high resistance rates 5
• Tenofovir disoproxil fumarate provides potent anti-HBV activity at the standard 300 mg daily dose 5

If Renal Impairment Develops with HBV Coinfection:

Switch to tenofovir alafenamide (TAF)-based regimen rather than discontinuing tenofovir entirely. 7, 8

• TAF requires no dose adjustment for eGFR ≥15 mL/min, providing superior renal safety compared to TDF 7
• TAF maintains anti-HBV efficacy comparable to TDF while reducing nephrotoxicity risk 7, 8
• The 2022 Korean Association for the Study of the Liver specifically recommends TAF over TDF for patients with or at risk for renal dysfunction 7

Critical warning: Abrupt discontinuation of anti-HBV therapy can cause severe hepatitis flares, hepatic decompensation, and death 5

Management of Drug Intolerance

If intolerance to any component of TLD develops, switch to an alternative integrase inhibitor-based regimen maintaining the same backbone NRTIs, or switch to a two-drug regimen if tenofovir is the problematic agent. 1

Specific Intolerance Scenarios:

Dolutegravir intolerance (e.g., neuropsychiatric effects, insomnia):

• Switch to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) 1
• This maintains integrase inhibitor potency with potentially better tolerability 1

Tenofovir disoproxil fumarate intolerance (e.g., gastrointestinal symptoms, bone density concerns):

• Switch to dolutegravir plus lamivudine as a two-drug regimen 1
• Alternative: Switch to bictegravir/emtricitabine/tenofovir alafenamide for improved bone and renal safety 1

Lamivudine intolerance (rare):

• Switch lamivudine to emtricitabine (functionally equivalent) 1
• Continue dolutegravir with tenofovir disoproxil fumarate/emtricitabine 1

Monitoring Requirements

Monitor renal function (serum creatinine, creatinine clearance, serum phosphorus, urine glucose, and urine protein) at baseline and at clinically appropriate intervals throughout therapy. 7, 3

• Baseline assessment is mandatory before initiating tenofovir-containing regimens 7
• More frequent monitoring is required in patients with baseline CrCl <60 mL/min or risk factors for renal disease 3, 4
• Viral load should be checked at 1 month after any regimen switch, then every 3 months for the first year 1

Common Pitfalls to Avoid

• Never discontinue tenofovir or lamivudine abruptly in HBV-coinfected patients without ensuring alternative anti-HBV coverage 5
• Do not use standard TLD dosing in patients with CrCl <50 mL/min without dose interval adjustment 3, 4
• Avoid switching to dolutegravir/lamivudine two-drug regimen in patients with chronic hepatitis B, as this eliminates tenofovir's anti-HBV activity 1, 7
• Screen for drug interactions using resources such as the University of Liverpool HIV Drug Interactions database before initiating therapy 9